These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

512 related items for PubMed ID: 26378169

  • 1. Structural and Thermodynamic Basis of Epitope Binding by Neutralizing and Nonneutralizing Forms of the Anti-HIV-1 Antibody 4E10.
    Rujas E, Gulzar N, Morante K, Tsumoto K, Scott JK, Nieva JL, Caaveiro JM.
    J Virol; 2015 Dec; 89(23):11975-89. PubMed ID: 26378169
    [Abstract] [Full Text] [Related]

  • 2. Interaction of anti-HIV type 1 antibody 2F5 with phospholipid bilayers and its relevance for the mechanism of virus neutralization.
    Maeso R, Huarte N, Julien JP, Kunert R, Pai EF, Nieva JL.
    AIDS Res Hum Retroviruses; 2011 Aug; 27(8):863-76. PubMed ID: 21142698
    [Abstract] [Full Text] [Related]

  • 3. Functional Contacts between MPER and the Anti-HIV-1 Broadly Neutralizing Antibody 4E10 Extend into the Core of the Membrane.
    Rujas E, Insausti S, García-Porras M, Sánchez-Eugenia R, Tsumoto K, Nieva JL, Caaveiro JM.
    J Mol Biol; 2017 Apr 21; 429(8):1213-1226. PubMed ID: 28300601
    [Abstract] [Full Text] [Related]

  • 4. Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions.
    Dennison SM, Stewart SM, Stempel KC, Liao HX, Haynes BF, Alam SM.
    J Virol; 2009 Oct 21; 83(19):10211-23. PubMed ID: 19640992
    [Abstract] [Full Text] [Related]

  • 5. HIV type 1 Env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies.
    Chakrabarti BK, Pancera M, Phogat S, O'Dell S, McKee K, Guenaga J, Robinson J, Mascola J, Wyatt RT.
    AIDS Res Hum Retroviruses; 2011 Aug 21; 27(8):877-87. PubMed ID: 21158699
    [Abstract] [Full Text] [Related]

  • 6. Interactions between lipids and human anti-HIV antibody 4E10 can be reduced without ablating neutralizing activity.
    Xu H, Song L, Kim M, Holmes MA, Kraft Z, Sellhorn G, Reinherz EL, Stamatatos L, Strong RK.
    J Virol; 2010 Jan 21; 84(2):1076-88. PubMed ID: 19906921
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function.
    Guenaga J, Wyatt RT.
    PLoS Pathog; 2012 Jan 21; 8(7):e1002806. PubMed ID: 22829767
    [Abstract] [Full Text] [Related]

  • 10. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.
    Julien JP, Huarte N, Maeso R, Taneva SG, Cunningham A, Nieva JL, Pai EF.
    J Virol; 2010 May 21; 84(9):4136-47. PubMed ID: 20147404
    [Abstract] [Full Text] [Related]

  • 11. Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles.
    Phogat S, Svehla K, Tang M, Spadaccini A, Muller J, Mascola J, Berkower I, Wyatt R.
    Virology; 2008 Mar 30; 373(1):72-84. PubMed ID: 18155743
    [Abstract] [Full Text] [Related]

  • 12. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1.
    Zwick MB, Jensen R, Church S, Wang M, Stiegler G, Kunert R, Katinger H, Burton DR.
    J Virol; 2005 Jan 30; 79(2):1252-61. PubMed ID: 15613352
    [Abstract] [Full Text] [Related]

  • 13. Functional Optimization of Broadly Neutralizing HIV-1 Antibody 10E8 by Promotion of Membrane Interactions.
    Rujas E, Leaman DP, Insausti S, Ortigosa-Pascual L, Zhang L, Zwick MB, Nieva JL.
    J Virol; 2018 Apr 15; 92(8):. PubMed ID: 29386285
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.